SCHEMBL3518356

SCHEMBL3518356

NC(=O)c1c2ccccc2nc2c1[nH]c1ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.54
TERT O14746 4/20 0.51
TP53 P04637 2/20 0.47
NPC1 O15118 1/20 0.47
POLB P06746 1/20 0.47
CASP1 P29466 1/20 0.47
RAB9A P51151 1/20 0.47
MAPK10 P53779 1/20 0.47
CASP7 P55210 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ELANE P08246 1/20 0.45
KDM4E B2RXH2 1/20 0.45
MAP2 P11137 1/20 0.43
PIM1 P11309 2/20 0.43
PIM3 Q86V86 2/20 0.43
PIM2 Q9P1W9 1/20 0.43
LIMK1 P53667 1/20 0.41
ALDH1A1 P00352 1/20 0.40
THRB P10828 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30805773 1.00 DYRK1A (0.54) DYRK1ATERTTP53NPC1POLB
SCHEMBL30192723 0.88 TERT (0.53) DYRK1ATERTTP53NPC1POLB
SCHEMBL3290014 0.88 DYRK1A (0.56) DYRK1ATERTTP53NPC1POLB
SCHEMBL3123791 0.88 TERT (0.53) DYRK1ATERTTP53NPC1POLB
SCHEMBL30805770 0.88 DYRK1A (0.56) DYRK1ATERTTP53NPC1POLB
SCHEMBL3291598 0.86 RXFP1 (0.46) DYRK1ATERTTP53ALDH1A1
SCHEMBL9390934 0.85 TERT (0.51) DYRK1ATERTTP53NPC1POLB
SCHEMBL29196428 0.85 TERT (0.54) DYRK1ATERTTP53NPC1POLB
SCHEMBL13338301 0.85 TERT (0.48) DYRK1ATERTTP53NPC1POLB
SCHEMBL3400668 0.83 KDM4E (0.47) DYRK1ATERTTP53CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2007511573-A 2007-05-10 JP claimed
EP-1687304-A1 SUBSTITUTED QUINOLINES FOR THE TREATMENT OF CANCER Crystax Pharmaceuticals S.L. (ES) 2006-08-09 EP claimed
WO-2005054236-A1 SUBSTITUTED QUINOLINES FOR THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS S.L. (ES) 2005-06-16 WO claimed
US-20240293366-A1 TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASES AZORA THERAPEUTICS, INC. 2024-09-05 US disclosed
CN-117683030-A Baiphylline derivative containing acylhydrazone structure, and preparation method and application thereof 南开大学 2024-03-12 CN disclosed
EP-4252844-A2 TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASES AZORA THERAPEUTICS, INC. (US) 2023-10-04 EP disclosed
CN-114206312-A Topical compositions and methods for treating inflammatory skin disorders 阿佐拉治疗股份有限公司 2022-03-18 CN disclosed
US-20220023259-A1 TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASES AZORA THERAPEUTICS, INC. 2022-01-27 US disclosed
US-11154533-B2 Topical compositions and methods for treating inflammatory skin diseases AZORA THERAPEUTICS, INC. (US) 2021-10-26 US disclosed
US-20210186931-A1 TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASES AZORA THERAPEUTICS, INC. 2021-06-24 US disclosed
US-20100331355-A1 Substituted Quinolines for the Treatment of Cancer CRYSTAX PHARMACEUTICALS, S.L. (ES) 2010-12-30 US disclosed
EP-1687304-A1 SUBSTITUTED QUINOLINES FOR THE TREATMENT OF CANCER Crystax Pharmaceuticals S.L. (ES) 2006-08-09 EP disclosed
WO-2005054236-A1 SUBSTITUTED QUINOLINES FOR THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS S.L. (ES) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210186931-A1 TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASES AHR, ARNT, TLR8 DYRK1A 859/4885TERT 2599/4885TP53 1820/4885
US-11154533-B2 Topical compositions and methods for treating inflammatory skin diseases AHR, ARNT, TLR8 DYRK1A 859/4885TERT 2599/4885TP53 1820/4885
US-20100331355-A1 Substituted Quinolines for the Treatment of Cancer TOP2B, TOP1, TOP2A DYRK1A 3740/4885TERT 1447/4885TP53 557/4885
US-20240293366-A1 TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASES AHR, ARNT, TLR8 DYRK1A 859/4885TERT 2599/4885TP53 1820/4885
US-20220023259-A1 TOPICAL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY SKIN DISEASES AHR, ARNT, TLR8 DYRK1A 859/4885TERT 2599/4885TP53 1820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.